{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:31:53Z","timestamp":1792485113861,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100019398","name":"Beijing Friendship Hospital","doi-asserted-by":"crossref","award":["YYZZ202215"],"award-info":[{"award-number":["YYZZ202215"]}],"id":[{"id":"10.13039\/501100019398","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2023YFC2507300"],"award-info":[{"award-number":["2023YFC2507300"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-024-03460-z","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T17:02:46Z","timestamp":1729789366000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Risk of Clostridioides difficile infection in inflammatory bowel disease patients undergoing vedolizumab treatment: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Wei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuelun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,24]]},"reference":[{"issue":"5","key":"3460_CR1","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","volume":"158","author":"JD Feuerstein","year":"2020","unstructured":"Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S. AGA Clinical Practice guidelines on the management of moderate to severe Ulcerative Colitis. Gastroenterology. 2020;158(5):1450\u201361.","journal-title":"Gastroenterology"},{"issue":"1","key":"3460_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","volume":"14","author":"J Torres","year":"2020","unstructured":"Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, Adamina M, Armuzzi A, Bachmann O, Bager P, et al. ECCO Guidelines on therapeutics in Crohn\u2019s Disease: Medical Treatment. J Crohn\u2019s Colitis. 2020;14(1):4\u201322.","journal-title":"J Crohn\u2019s Colitis"},{"issue":"5","key":"3460_CR3","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1093\/ibd\/izy313","volume":"25","author":"B Click","year":"2019","unstructured":"Click B, Regueiro M. A practical guide to the Safety and Monitoring of New IBD therapies. Inflamm Bowel Dis. 2019;25(5):831\u201342.","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"3460_CR4","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699\u2013710.","journal-title":"N Engl J Med"},{"issue":"5","key":"3460_CR5","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","volume":"66","author":"J-F Colombel","year":"2017","unstructured":"Colombel J-F, Sands BE, Rutgeerts P, Sandborn W, Danese S, D\u2019Haens G, Panaccione R, Loftus EV, Sankoh S, Fox I, et al. The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease. Gut. 2017;66(5):839\u201351.","journal-title":"Gut"},{"issue":"2","key":"3460_CR6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.cgh.2020.12.030","volume":"20","author":"J Kirchgesner","year":"2022","unstructured":"Kirchgesner J, Desai RJ, Beaugerie L, Schneeweiss S, Kim SC. Risk of serious infections with Vedolizumab Versus Tumor necrosis factor antagonists in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2022;20(2):314\u2013e324316.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"3460_CR7","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/ecco-jcc\/jjab052","volume":"15","author":"T Kucharzik","year":"2021","unstructured":"Kucharzik T, Ellul P, Greuter T, Rahier JF, Verstockt B, Abreu C, Albuquerque A, Allocca M, Esteve M, Farraye FA, et al. ECCO Guidelines on the Prevention, diagnosis, and management of infections in inflammatory bowel disease. J Crohns Colitis. 2021;15(6):879\u2013913.","journal-title":"J Crohns Colitis"},{"issue":"8","key":"3460_CR8","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/ajg.2016.187","volume":"111","author":"R Razik","year":"2016","unstructured":"Razik R, Rumman A, Bahreini Z, McGeer A, Nguyen GC. Recurrence of Clostridium difficile infection in patients with inflammatory bowel disease: the RECIDIVISM Study. Am J Gastroenterol. 2016;111(8):1141\u20136.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"3460_CR9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.cgh.2006.12.028","volume":"5","author":"M Issa","year":"2007","unstructured":"Issa M, Vijayapal A, Graham MB, Beaulieu DB, Otterson MF, Lundeen S, Skaros S, Weber LR, Komorowski RA, Knox JF, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5(3):345\u201351.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"3460_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.crohns.2008.09.003","volume":"3","author":"P Bossuyt","year":"2009","unstructured":"Bossuyt P, Verhaegen J, Van Assche G, Rutgeerts P, Vermeire S. Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease. J Crohns Colitis. 2009;3(1):4\u20137.","journal-title":"J Crohns Colitis"},{"key":"3460_CR11","doi-asserted-by":"crossref","unstructured":"Alghamdi M, Alyousfi D, Mukhtar MS, Mosli M. Association between Vedolizumab and risk of clostridium difficile infection in patients with ulcerative colitis: a systematic review and meta-analysis. Saudi J Gastroenterol 2024.","DOI":"10.4103\/sjg.sjg_118_24"},{"key":"3460_CR12","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg 2021, 88.","DOI":"10.1016\/j.ijsu.2021.105906"},{"key":"3460_CR13","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160.","journal-title":"BMJ"},{"issue":"9","key":"3460_CR14","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.cgh.2012.02.004","volume":"10","author":"C Ha","year":"2012","unstructured":"Ha C, Ullman TA, Siegel CA, Kornbluth A. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol. 2012;10(9):1002\u20137. quiz e1078.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"3460_CR15","doi-asserted-by":"publisher","first-page":"otaa023","DOI":"10.1093\/crocol\/otaa023","volume":"360","author":"C Johnson","year":"2020","unstructured":"Johnson C, Barnes EL, Zhang X, Long MD. Trends and characteristics of clinical trials participation for inflammatory bowel disease in the United States: a Report from IBD partners. Crohns Colitis. 2020;360(2):otaa023.","journal-title":"Crohns Colitis"},{"issue":"7","key":"3460_CR16","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1177\/2050640619858050","volume":"7","author":"M Spadaccini","year":"2019","unstructured":"Spadaccini M, Aghemo A, Caprioli F, Lleo A, Invernizzi F, Danese S, Donato MF. Safety of vedolizumab in liver transplant recipients: a systematic review. United Eur Gastroenterol J. 2019;7(7):875\u201380.","journal-title":"United Eur Gastroenterol J"},{"issue":"8","key":"3460_CR17","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1080\/00365521.2023.2176252","volume":"58","author":"TH Wiken","year":"2023","unstructured":"Wiken TH, H\u00f8ivik ML, Buer L, Warren DJ, Bolstad N, Moum BA, Anisdahl K, Sm\u00e5stuen MC, Medhus AW. Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring. Scand J Gastroenterol. 2023;58(8):863\u201373.","journal-title":"Scand J Gastroenterol"},{"issue":"7","key":"3460_CR18","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1097\/MCG.0000000000001733","volume":"57","author":"RS Dalal","year":"2023","unstructured":"Dalal RS, Mitri J, Goodrick H, Allegretti JR. Risk of gastrointestinal infections after initiating Vedolizumab and Anti-TNF agents for Ulcerative Colitis. J Clin Gastroenterol. 2023;57(7):714\u201320.","journal-title":"J Clin Gastroenterol"},{"issue":"2","key":"3460_CR19","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/ecco-jcc\/jjz137","volume":"14","author":"RD Cohen","year":"2020","unstructured":"Cohen RD, Bhayat F, Blake A, Travis S. The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn\u2019s Disease: 4 years of global post-marketing data. J Crohn\u2019s Colitis. 2020;14(2):192\u2013204.","journal-title":"J Crohn\u2019s Colitis"},{"issue":"7","key":"3460_CR20","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1111\/apt.15177","volume":"49","author":"T Adar","year":"2019","unstructured":"Adar T, Faleck D, Sasidharan S, Cushing K, Borren NZ, Nalagatla N, Ungaro R, Sy W, Owen SC, Patel A, et al. Comparative safety and effectiveness of tumor necrosis factor \u03b1 antagonists and vedolizumab in elderly IBD patients: a multicentre study. Aliment Pharmacol Ther. 2019;49(7):873\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"3460_CR21","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1007\/s12325-021-01713-x","volume":"38","author":"N Khan","year":"2021","unstructured":"Khan N, Pernes T, Weiss A, Trivedi C, Patel M, Xie D, Yang YX. Incidence of infections and Malignancy among Elderly Male patients with IBD exposed to Vedolizumab, Prednisone, and 5-ASA medications: a Nationwide Retrospective Cohort Study. Adv Therapy. 2021;38(5):2586\u201398.","journal-title":"Adv Therapy"},{"key":"3460_CR22","unstructured":"Wells G, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, Tugwell PT. Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analys analysis http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp.Accessed 01\/09\/2023."},{"key":"3460_CR23","volume-title":"Methods Guide for Effectiveness and comparative effectiveness reviews","author":"M Viswanathan","year":"2008","unstructured":"Viswanathan M, Ansari MT, Berkman ND, Chang S, Hartling L, McPheeters M, Santaguida PL, Shamliyan T, Singh K, Tsertsvadze A, et al. : AHRQ methods for Effective Health Care:assessing the risk of Bias of Individual Studies in systematic reviews of Health Care interventions. Methods Guide for Effectiveness and comparative effectiveness reviews. edn. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008."},{"issue":"4","key":"3460_CR24","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1007\/s00464-020-08225-9","volume":"35","author":"W Chen","year":"2021","unstructured":"Chen W, Zhang YL, Zhao Y, Yang AM, Qian JM, Wu D. Endoscopic resection for non-polypoid dysplasia in inflammatory bowel disease: a systematic review and meta-analysis. Surg Endosc. 2021;35(4):1534\u201343.","journal-title":"Surg Endosc"},{"issue":"9","key":"3460_CR25","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/apt.15680","volume":"51","author":"M Hup\u00e9","year":"2020","unstructured":"Hup\u00e9 M, Rivi\u00e8re P, Nancey S, Roblin X, Altwegg R, Filippi J, Fumery M, Bouguen G, Peyrin-Biroulet L, Bourreille A, et al. Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study. Aliment Pharmacol Ther. 2020;51(9):852\u201360.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"3460_CR26","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/apt.15921","volume":"52","author":"M Bohm","year":"2020","unstructured":"Bohm M, Xu R, Zhang Y, Varma S, Fischer M, Kochhar G, Boland B, Singh S, Hirten R, Ungaro R, et al. Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn\u2019s disease. Aliment Pharmacol Ther. 2020;52(4):669\u201381.","journal-title":"Aliment Pharmacol Ther"},{"key":"3460_CR27","doi-asserted-by":"crossref","unstructured":"Kochar B, Jiang Y, Winn A, Barnes EL, Martin CF, Long MD, Kappelman MD. The early experience with vedolizumab in the United States. Crohn\u2019s Colitis 360 2019;1(3).","DOI":"10.1093\/crocol\/otz027"},{"issue":"9","key":"3460_CR28","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1177\/2050640620948802","volume":"8","author":"FS Macaluso","year":"2020","unstructured":"Macaluso FS, Fries W, Renna S, Viola A, Muscianisi M, Cappello M, Guida L, Siringo S, Camilleri S, Garufi S, et al. Effectiveness and safety of vedolizumab in biologically na\u00efve patients: a real-world multi-centre study. United Eur Gastroenterol J. 2020;8(9):1045\u201355.","journal-title":"United Eur Gastroenterol J"},{"issue":"3","key":"3460_CR29","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/MIB.0000000000001039","volume":"23","author":"U Kopylov","year":"2017","unstructured":"Kopylov U, Ron Y, Avni-Biron I, Koslowsky B, Waterman M, Daher S, Ungar B, Yanai H, Maharshak N, Ben-Bassat O, et al. Efficacy and safety of Vedolizumab for induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World experience. Inflamm Bowel Dis. 2017;23(3):404\u20138.","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"3460_CR30","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1093\/ibd\/izy153","volume":"24","author":"SC Ng","year":"2018","unstructured":"Ng SC, Hilmi IN, Blake A, Bhayat F, Adsul S, Khan QR, Wu DC. Low frequency of opportunistic infections in patients receiving vedolizumab in clinical trials and post-marketing setting. Inflamm Bowel Dis. 2018;24(11):2431\u201341.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"3460_CR31","doi-asserted-by":"publisher","first-page":"S","DOI":"10.1016\/S0016-5085(18)30682-6","volume":"154","author":"B Kochar","year":"2018","unstructured":"Kochar B, Winn A, Barnes EL, Long MD, Kappelman M. The National Experience with Vedolizumab. Gastroenterology. 2018;154(6):S-67-S-68.","journal-title":"Gastroenterology"},{"issue":"3","key":"3460_CR32","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/apt.14167","volume":"46","author":"A Amiot","year":"2017","unstructured":"Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, et al. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther. 2017;46(3):310\u201321.","journal-title":"Aliment Pharmacol Ther"},{"key":"3460_CR33","doi-asserted-by":"publisher","first-page":"S434","DOI":"10.1093\/ecco-jcc\/jjy222.758","volume":"13","author":"ATM Gan","year":"2019","unstructured":"Gan ATM, Chan WPW, Ling KL, Hartono LJ, Ong DE, Gowans M, Lin H, Lim WC, Tan MTK, Ong JPL, et al. Real-world data on the efficacy and safety of vedolizumab therapy in patients with inflammatory bowel disease: a retrospective nation-wide cohort study in Singapore. J Crohn\u2019s Colitis. 2019;13:S434\u20135.","journal-title":"J Crohn\u2019s Colitis"},{"key":"3460_CR34","first-page":"364","volume":"10","author":"A Buisson","year":"2022","unstructured":"Buisson A, Nachury M, Guilmoteau T, Altwegg R, Treton X, Fumery M, Serrero M, Leclerc E, Caillo L, Pereira B, et al. Real-world multicenter comparison of short and long-term effectiveness and safety between Tofacitinib and Vedolizumab in patients with Ulcerative Colitis after failure to at least one Anti-TNF Agent. United Eur Gastroenterol J. 2022;10:364\u20135.","journal-title":"United Eur Gastroenterol J"},{"issue":"8","key":"3460_CR35","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.cgh.2018.09.035","volume":"17","author":"J Meserve","year":"2019","unstructured":"Meserve J, Aniwan S, Koliani-Pace JL, Shashi P, Weiss A, Faleck D, Winters A, Chablaney S, Kochhar G, Boland BS, et al. Retrospective analysis of Safety of Vedolizumab in patients with inflammatory Bowel diseases. Clin Gastroenterol Hepatol. 2019;17(8):1533\u2013e15401532.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"3460_CR36","doi-asserted-by":"publisher","first-page":"S235","DOI":"10.1016\/S0016-5085(15)30772-1","volume":"148","author":"K O\u2019Regan","year":"2015","unstructured":"O\u2019Regan K, Kroeker K, Halloran BP, Dieleman LA, Peterson A, Haynes K, Fedorak RN. A retrospective cohort study of rates of clostridium difficile infection in moderate-to-severe inflammatory bowel disease patients treated with vedolizumab vs. infliximab at a Canadian tertiary hospital. Gastroenterology. 2015;148(4):S235.","journal-title":"Gastroenterology"},{"issue":"6","key":"3460_CR37","doi-asserted-by":"publisher","first-page":"S","DOI":"10.1016\/S0016-5085(18)32861-0","volume":"154","author":"G Lawlor","year":"2018","unstructured":"Lawlor G, Bohm M, Advani R, Tricomi B, Gutta A, Phipps M, Adlakha N, Rosen MH, Malter L, Hudesman D, et al. Safety and Efficacy of Biologic therapies for Inflammatory Bowel Disease in patients with primary sclerosing Cholangitis: an IBD Remedy Study. Gastroenterology. 2018;154(6):S\u2013843.","journal-title":"Gastroenterology"},{"key":"3460_CR38","first-page":"157","volume":"34","author":"S Morrison","year":"2019","unstructured":"Morrison S, Edwards G, Foster R, Daley A, Lawrence O, Goodsall T. The safety and efficacy of vedolizumab for Crohn\u2019s disease and ulcerative colitis in the Hunter New England region. J Gastroenterol Hepatol. 2019;34:157.","journal-title":"J Gastroenterol Hepatol"},{"issue":"8","key":"3460_CR39","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/apt.14930","volume":"48","author":"M Chaparro","year":"2018","unstructured":"Chaparro M, Garre A, Ricart E, Iborra M, Mesonero F, Vera I, Riestra S, Garc\u00eda-S\u00e1nchez V, Luisa De Castro M, Martin-Cardona A, et al. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. Aliment Pharmacol Ther. 2018;48(8):839\u201351.","journal-title":"Aliment Pharmacol Ther"},{"key":"3460_CR40","doi-asserted-by":"publisher","first-page":"i326","DOI":"10.1093\/ecco-jcc\/jjab232.423","volume":"16","author":"A Alshahrani","year":"2022","unstructured":"Alshahrani A, Alzahrani DMMA, Narula N. Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: a retrospective cohort study. J Crohn\u2019s Colitis. 2022;16:i326.","journal-title":"J Crohn\u2019s Colitis"},{"issue":"30","key":"3460_CR41","doi-asserted-by":"publisher","first-page":"4428","DOI":"10.3748\/wjg.v26.i30.4428","volume":"26","author":"SS Reddy Pulusu","year":"2020","unstructured":"Reddy Pulusu SS, Srinivasan A, Krishnaprasad K, Cheng D, Begun J, Keung C, Van Langenberg D, Thin L, Mogilevski T, de Cruz P, et al. Vedolizumab for ulcerative colitis: real world outcomes from a multicenter observational cohort of Australia and Oxford. World J Gastroenterol. 2020;26(30):4428\u201341.","journal-title":"World J Gastroenterol"},{"issue":"9","key":"3460_CR42","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41395-018-0162-0","volume":"113","author":"N Narula","year":"2018","unstructured":"Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L, et al. Vedolizumab for Ulcerative Colitis: treatment outcomes from the VICTORY Consortium. Am J Gastroenterol. 2018;113(9):1345\u201354.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"3460_CR43","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1590\/s0004-2803.201900000-58","volume":"56","author":"RL Perin","year":"2019","unstructured":"Perin RL, Dami\u00e3o AOMC, Flores C, Ludvig JC, Magro DO, Miranda EF, de Moraes AC, Nones RB, Teixeira FV, Zeroncio M, et al. Vedolizumab in the management of inflammatory bowel diseases: a Brazilian observational multicentric study. Arq Gastroenterol. 2019;56(3):312\u20137.","journal-title":"Arq Gastroenterol"},{"issue":"10","key":"3460_CR44","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/apt.13594","volume":"43","author":"DC Baumgart","year":"2016","unstructured":"Baumgart DC, Bokemeyer B, Drabik A, Stallmach A, Schreiber S, Atreya R, Bachmann O, Busse K, Bl\u00e4ker M, B\u00f6rner N, et al. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - A nationwide consecutive German cohort study. Aliment Pharmacol Ther. 2016;43(10):1090\u2013102.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"3460_CR45","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1177\/2050640620951400","volume":"8","author":"NA Cohen","year":"2020","unstructured":"Cohen NA, Plevris N, Kopylov U, Grinman A, Ungar B, Yanai H, Leibovitzh H, Isakov NF, Hirsch A, Ritter E, et al. Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study. United Eur Gastroenterol J. 2020;8(9):1076\u201385.","journal-title":"United Eur Gastroenterol J"},{"issue":"6","key":"3460_CR46","doi-asserted-by":"publisher","first-page":"S","DOI":"10.1016\/S0016-5085(20)32391-X","volume":"158","author":"K Leung","year":"2020","unstructured":"Leung K, Jackson CS, Hammami MB. Vedolizumab is safe in veteran patients with inflammatory bowel Disease over Age 65: Retrospective Cohort. Gastroenterology. 2020;158(6):S\u2013680.","journal-title":"Gastroenterology"},{"issue":"10","key":"3460_CR47","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1097\/MIB.0000000000000918","volume":"22","author":"MA Conrad","year":"2016","unstructured":"Conrad MA, Stein RE, Maxwell EC, Albenberg L, Baldassano RN, Dawany N, Grossman AB, Mamula P, Piccoli DA, Kelsen JR. Vedolizumab Therapy in severe Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016;22(10):2425\u201331.","journal-title":"Inflamm Bowel Dis"},{"key":"3460_CR48","first-page":"A188","volume":"24","author":"C Garay","year":"2017","unstructured":"Garay C, Oro M, Senra L, G\u00f3mez M, Fern\u00e1ndez A, De Ilarduya EM, Lizama N, G\u00f3mez A, Mart\u00ednez JJ, Valero M. Vedolizumab treatment for inflammatory bowel disease: clinical practice. Eur J Hosp Pharm. 2017;24:A188\u20139.","journal-title":"Eur J Hosp Pharm"},{"issue":"4","key":"3460_CR49","doi-asserted-by":"publisher","first-page":"S974","DOI":"10.1016\/S0016-5085(16)33301-7","volume":"150","author":"K Chaudrey","year":"2016","unstructured":"Chaudrey K, Whitehead D, Dulai PS, Peerani F, Narula N, Hudesman D, Shmidt E, Lukin DJ, Swaminath A, Nguyen N, et al. Safety of vedolizumab in inflammatory bowel disease in a multi-center real world consortium. Gastroenterology. 2016;150(4):S974.","journal-title":"Gastroenterology"},{"issue":"2","key":"3460_CR50","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1136\/gut.2007.128231","volume":"57","author":"AN Ananthakrishnan","year":"2008","unstructured":"Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57(2):205\u201310.","journal-title":"Gut"},{"issue":"2","key":"3460_CR51","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1053\/j.gastro.2017.04.044","volume":"153","author":"H Singh","year":"2017","unstructured":"Singh H, Nugent Z, Yu BN, Lix LM, Targownik LE, Bernstein CN. Higher incidence of Clostridium difficile infection among individuals with inflammatory bowel disease. Gastroenterology. 2017;153(2):430\u2013e438432.","journal-title":"Gastroenterology"},{"issue":"8","key":"3460_CR52","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1093\/ibd\/izy086","volume":"24","author":"GE Barber","year":"2018","unstructured":"Barber GE, Hendler S, Okafor P, Limsui D, Limketkai BN. Rising incidence of intestinal infections in inflammatory bowel disease: a nationwide analysis. Inflamm Bowel Dis. 2018;24(8):1849\u201356.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"3460_CR53","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1007\/s10620-021-07200-1","volume":"67","author":"L Tsai","year":"2022","unstructured":"Tsai L, Nguyen NH, Ma C, Prokop LJ, Sandborn WJ, Singh S. Systematic review and Meta-analysis: risk of hospitalization in patients with Ulcerative Colitis and Crohn\u2019s Disease in Population-based Cohort studies. Dig Dis Sci. 2022;67(6):2451\u201361.","journal-title":"Dig Dis Sci"},{"issue":"3","key":"3460_CR54","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.cgh.2006.12.027","volume":"5","author":"JF Rodemann","year":"2007","unstructured":"Rodemann JF, Dubberke ER, Reske KA, Seo DH, Stone CD. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5(3):339\u201344.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"3460_CR55","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","volume":"7","author":"JS Lasa","year":"2022","unstructured":"Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(2):161\u201370.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"3460_CR56","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1136\/gutjnl-2022-328052","volume":"72","author":"B Barberio","year":"2023","unstructured":"Barberio B, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn\u2019s disease: systematic review and network meta-analysis. Gut. 2023;72(2):264\u201374.","journal-title":"Gut"},{"issue":"1","key":"3460_CR57","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjy143","volume":"13","author":"B Balram","year":"2019","unstructured":"Balram B, Battat R, Al-Khoury A, D\u2019Aoust J, Afif W, Bitton A, Lakatos PL, Bessissow T. Risk factors Associated with Clostridium difficile infection in inflammatory bowel disease: a systematic review and Meta-analysis. J Crohns Colitis. 2019;13(1):27\u201338.","journal-title":"J Crohns Colitis"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03460-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-024-03460-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03460-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T18:04:05Z","timestamp":1729793045000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-024-03460-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3460"],"URL":"https:\/\/doi.org\/10.1186\/s12876-024-03460-z","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,24]]},"assertion":[{"value":"9 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Ethics and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"377"}}